A compound as shown in formula (II): wherein is selected from a single bond or a double bond; X is selected from the group consisting of C(R 3 ), CH(R 3 ), N and N(R 3 ); Y is selected from the group consisting of N(R 5 ) and O; ring A is selected from the group consisting of phenyl and 5- to 6-membered heteroaryl; R 1 is selected from 5- to 10-membered heteroaryl optionally substituted with one, two or three R group(s); R 2 is selected from the group consisting of H, F, Cl, Br, I, OH, and NH 2 , or selected from the group consisting of C 1-6 alkyl, C 1-3 heteroalkyl, 5- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, each optionally substituted with one, two or three R group(s); R 3 is selected from the group consisting of H, F, Cl, Br, I, OH, and NH 2 ; R 4 is selected from H, or selected from the group consisting of C 1-3 alkyl and C 1-3 alkoxy; R 5 is selected from H, or selected from the group consisting of C 1-8 alkyl, C 3-7 cycloalkyl and 3- to 6-membered heterocycloalkyl, each optionally substituted with one, two or three R group(s); R 6 is selected from H, or selected from C 1-6 alkyl; or R 5 and R 6 are joined together to form a 5- to 6-membered ring; R is selected from the group consisting of H, F, Cl, Br, I, OH, and NH 2 , and NH 2 -(C=O)-, or selected from the group consisting of C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkyl-NH-(C=O)-, C 1-3 alkyl-S(=O) 2 -, C 3-6 cycloalkyl, 3- to 6- membered heterocycloalkyl and phenyl; the "hetero" in the 5- to 10-membered heteroaryl, C 1-3 heteroalkyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and 3- to 6-membered heterocycloalkyl is respectively and independently selected from the group consisting of -NH-, N, -O-, -S-, -S(=O) 2 - and -NH-C(=O)-; in any of the above cases, the number of heteroatoms or heteroatomic groups is respectively and independently selected from 1, 2 or 3, a pharmaceutically acceptable salt and a tautomer thereof. is selected from a single bond or a double bond; X is selected from the group consisting of C(R 3 ), CH(R 3 ), N and N(R 3 ); Y is selected from the group consisting of N(R 5 ) and O; ring A is selected from the group consisting of phenyl and 5- to 6-membered heteroaryl; R 1 is selected from 5- to 10-membered heteroaryl optionally substituted with one, two or three R group(s); R 2 is selected from the group consisting of H, F, Cl, Br, I, OH, and NH 2 , or selected from the group consisting of C 1-6 alkyl, C 1-3 heteroalkyl, 5- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, each optionally substituted with one, two or three R group(s); R 3 is selected from the group consisting of H, F, Cl, Br, I, OH, and NH 2 ; R 4 is selected from H, or selected from the group consisting of C 1-3 alkyl and C 1-3 alkoxy; R 5 is selected from H, or selected from the group consisting of C 1-8 alkyl, C 3-7 cycloalkyl and 3- to 6-membered heterocycloalkyl, each optionally substituted with one, two or three R group(s); R 6 is selected from H, or selected from C 1-6 alkyl; or R 5 and R 6 are joined together to form a 5- to 6-membered ring; R is selected from the group consisting of H, F, Cl, Br, I, OH, and NH 2 , and NH 2 -(C=O)-, or selected from the group consisting of C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkyl-NH-(C=O)-, C 1-3 alkyl-S(=O) 2 -, C 3-6 cycloalkyl, 3- to 6- membered heterocycloalkyl and phenyl; the "hetero" in the 5- to 10-membered heteroaryl, C 1-3 heteroalkyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and 3- to 6-membered heterocycloalkyl is respectively and independently selected from the group consisting of -NH-, N, -O-, -S-, -S(=O) 2 - and -NH-C(=O)-; in any of the above cases, the number of heteroatoms or heteroatomic groups is respectively and independently selected from 1, 2 or 3, a pharmaceutically acceptable salt and a tautomer thereof. <EOS>